Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma

Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related deaths worldwide. Various molecular markers in NSCLC patients have been developed, including gene rearrangements, currently used in therapeutic strategies. With increasing number of these molecular biomarkers of NSCLC, there is a demand for highly efficient methods for detecting mutations and translocations in treatable targets. Those currently available U.S. Food and Drug Administration (FDA) approved approaches, for example imunohistochemisty (IHC) and fluorescence in situ hybridization (FISH), are inadequate, due to sufficient quantity of material and long time duration. Next-generation massive parallel sequencing (NGS), with the ability to perform and capture data from millions of sequencing reactions simultaneously could resolve the problem. Thanks to gradual NGS introduction into clinical laboratories, screening time should be considerably shorter, which is very important for patients with advanced NSCLC. Moreover, only a minimum sample input is needed for achieving adequate results. NGS was compared to the current detection methods of ALK, ROS1, c-RET and c-MET rearrangements in NSCLC and a significant match, between IHC, FISH and NGS results, was found. Recent available researches have been carried out on a small numbers of patients. Verifying these results on larger patients cohort is important. This review sumarizes the literature on this subject and compares current possibilities of predictive gene rearrangements detection in patients with NSCLC.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:164

Enthalten in:

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia - 164(2020), 2 vom: 15. Juni, Seite 127-132

Sprache:

Englisch

Beteiligte Personen:

Brisudova, Aneta [VerfasserIn]
Skarda, Jozef [VerfasserIn]

Links:

Volltext

Themen:

ALK protein, human
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Fluorescence in situ hybridization
Gene rearrangement
Immunohistochemistry
Journal Article
MET protein, human
Next-generation sequencing
Non-small cel lung carcinoma
Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-met
Proto-Oncogene Proteins c-ret
RET protein, human
ROS1 protein, human
Review

Anmerkungen:

Date Completed 26.04.2021

Date Revised 26.04.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.5507/bp.2020.015

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM308696360